

Jonathan G Pol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6393909/publications.pdf>

Version: 2024-02-01

80
papers

5,008
citations

101384

36
h-index

95083

68
g-index

89
all docs

89
docs citations

89
times ranked

8156
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases. <i>Oncolimmunology</i> , 2022, 11, 2029299.	2.1	4
2	Improved Swiss-rolling method for histological analyses of colon tissue. <i>MethodsX</i> , 2022, 9, 101630.	0.7	7
3	NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 695-706.	2.0	3
4	Circular RNAs as Potential Biomarkers in Breast Cancer. <i>Biomedicines</i> , 2022, 10, 725.	1.4	26
5	Local anesthetics elicit immune-dependent anticancer effects. , 2022, 10, e004151.		11
6	Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer. , 2022, 10, e004280.		7
7	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
8	Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. <i>Oncolimmunology</i> , 2021, 10, 1968595.	2.1	1
9	Tumor-intrinsic determinants of immunogenic cell death modalities. <i>Oncolimmunology</i> , 2021, 10, 1893466.	2.1	30
10	Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1260.	1.7	13
11	Valeur pronostique et prédictive de l'Immunescore dans les cancers du colon et de la vessie. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2021, N° 2, 113-118.	0.0	0
12	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	20
13	Alternative splicing of viral transcripts: the dark side of HBV. <i>Gut</i> , 2021, 70, 2373-2382.	6.1	18
14	Trial watch: intratumoral immunotherapy. <i>Oncolimmunology</i> , 2021, 10, 1984677.	2.1	31
15	Immune contexture of cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 70-76.	1.0	16
16	Effects of interleukin-2 in immunostimulation and immunosuppression. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	100
17	The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. <i>Pharmacological Research</i> , 2020, 161, 105249.	3.1	13
18	Dynamical Boolean Modeling of Immunogenic Cell Death. <i>Frontiers in Physiology</i> , 2020, 11, 590479.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Autophagy-mediated metabolic effects of aspirin. <i>Cell Death Discovery</i> , 2020, 6, 129.	2.0	17
20	Cytokines in oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 4-27.	3.2	33
21	Repurposing CD8 ⁺ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. <i>Oncolmmunology</i> , 2020, 9, 1794424.	2.1	10
22	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
23	Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. , 2020, 8, e000981.		15
24	Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). <i>Cell Death and Disease</i> , 2020, 11, 502.	2.7	16
25	FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin. <i>Oncolmmunology</i> , 2020, 9, 1755214.	2.1	15
26	Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy. , 2020, 8, e000462.		43
27	Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. <i>Methods in Molecular Biology</i> , 2020, 2058, 191-211.	0.4	7
28	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , 2020, 12, e11622.	3.3	67
29	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. <i>Cell Metabolism</i> , 2019, 30, 754-767.e9.	7.2	67
30	The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1017.	1.7	115
31	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , 2019, 8, e1657375.	2.1	56
32	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl Î±-Ketoglutarate. <i>Cell Reports</i> , 2019, 27, 820-834.e9.	2.9	36
33	Tumor lysis with LTX-401 creates anticancer immunity. <i>Oncolmmunology</i> , 2019, 8, e1594555.	2.1	26
34	Trial watch: dietary interventions for cancer therapy. <i>Oncolmmunology</i> , 2019, 8, e1591878.	2.1	52
35	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
36	Anticancer effects of anti-CD47 immunotherapy <i>in vivo</i> . <i>Oncolmmunology</i> , 2019, 8, 1550619.	2.1	32

#	ARTICLE	IF	CITATIONS
37	Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. <i>Methods in Molecular Biology</i> , 2019, 1884, 297-315.	0.4	51
38	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. <i>Oncolmmunology</i> , 2019, 8, e1512329.	2.1	53
39	Une triade synergique de chimiothérapie, d'inhibiteurs de points de contrôle immunitaire et de mimétiques de la restriction calorique éradique des tumeurs dans un modèle préclinique murin. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2019, N° 4, 394-395.	0.0	0
40	Heating it up: Oncolytic viruses make tumors "hot" and suitable for checkpoint blockade immunotherapies. <i>Oncolmmunology</i> , 2018, 7, e1442169.	2.1	85
41	Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance. , 2018, , 215-229.		9
42	Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. <i>Trends in Immunology</i> , 2018, 39, 209-221.	2.9	153
43	Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 117-128.	6.0	34
44	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1511506.	2.1	121
45	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>Oncolmmunology</i> , 2018, 7, e1484980.	2.1	24
46	Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 654.	2.2	42
47	HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. <i>Cell Reports</i> , 2018, 24, 642-654.	2.9	19
48	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolmmunology</i> , 2018, 7, e1503032.	2.1	67
49	Metabolic vulnerability of cisplatin-resistant cancers. <i>EMBO Journal</i> , 2018, 37, .	3.5	84
50	Metabolic effects of fasting on human and mouse blood in vivo. <i>Autophagy</i> , 2017, 13, 567-578.	4.3	75
51	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
52	Customized Viral Immunotherapy for HPV-Associated Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 847-859.	1.6	32
53	Trial watch: DNA-based vaccines for oncological indications. <i>Oncolmmunology</i> , 2017, 6, e1398878.	2.1	30
54	Abstract 4557: Tumor immune profiling identifies multiple unique therapeutic targets that improve vaccination + oncolytic virotherapy against metastatic ovarian cancer. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
55	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
56	Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. <i>Journal of Immunology</i> , 2016, 196, 4587-4595.	0.4	35
57	S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. <i>Nature Immunology</i> , 2016, 17, 514-522.	7.0	67
58	Fasting improves anticancer immunosurveillance via autophagy induction in malignant cells. <i>Cell Cycle</i> , 2016, 15, 3327-3328.	1.3	17
59	Autophagy induction for the treatment of cancer. <i>Autophagy</i> , 2016, 12, 1962-1964.	4.3	50
60	Trial Watch: Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
61	First oncolytic virus approved for melanoma immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1115641.	2.1	247
62	Abstract A53: Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment.., 2016, , .		0
63	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
64	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
65	Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-stimulated signaling pathways and limits the extent of liver inflammation. <i>FASEB Journal</i> , 2015, 29, 1879-1889.	0.2	18
66	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
67	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
68	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolmmunology</i> , 2014, 3, e954929.	2.1	40
69	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e28185.	2.1	36
70	Trial Watch:. <i>Oncolmmunology</i> , 2014, 3, e28694.	2.1	95
71	Maraba Virus as a Potent Oncolytic Vaccine Vector. <i>Molecular Therapy</i> , 2014, 22, 420-429.	3.7	134
72	Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. <i>Molecular Therapy</i> , 2014, 22, 123-131.	3.7	93

#	ARTICLE	IF	CITATIONS
73	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmmunology</i> , 2014, 3, e963424.	2.1	62
74	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. <i>Molecular Therapy</i> , 2013, 21, 887-894.	3.7	98
75	Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. <i>Cancer Immunology Research</i> , 2013, 1, 309-319.	1.6	62
76	Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 ⁺ T-cell responses to anticancer vaccines. <i>Oncolmmunology</i> , 2013, 2, e26013.	2.1	51
77	Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8 ⁺ T-cell recall responses. <i>Blood</i> , 2013, 121, 2432-2439.	0.6	36
78	Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: Impact on HBV genotype monitoring. <i>Journal of Virological Methods</i> , 2008, 154, 1-6.	1.0	10
79	Expression of Defective Hepatitis B Virus Particles Derived from Singly Spliced RNA Is Related to Liver Disease. <i>Journal of Infectious Diseases</i> , 2008, 198, 218-225.	1.9	57
80	Oncolytic viruses: a step into cancer immunotherapy. <i>Virus Adaptation and Treatment</i> , 0, , 1.	1.5	4